Zhude Tu
University of Washington
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zhude Tu.
Chemistry Central Journal | 2016
Hermia Nalova Ikome; Fidele Ntie-Kang; Moses N. Ngemenya; Zhude Tu; Robert H. Mach; Simon M. N. Efange
BackgroundSigma (σ) receptors are membrane-bound proteins characterised by an unusual promiscuous ability to bind a wide variety of drugs and their high affinity for typical neuroleptic drugs, such as haloperidol, and their potential as alternative targets for antipsychotic agents. Sigma receptors display diverse biological activities and represent potential fruitful targets for therapeutic development in combating many human diseases. Therefore, they present an interesting avenue for further exploration. It was our goal to evaluate the potential of ring opened spipethiane (1) analogues as functional ligands (agonists) for σ receptors by chemical modification.ResultsChemical modification of the core structure of the lead compound, (1), by replacement of the sulphur atom with a carbonyl group, hydroxyl group and 3-bromobenzylamine with the simultaneous presence of 4-fluorobenzoyl replacing the spirofusion afforded novel potent sigma-1 receptor ligands 7a–f, 8a–f and 9d–e. The sigma-1 receptor affinities of 7e, 8a and 8f were slightly lower than that of 1 and their selectivities for this receptor two to threefold greater than that of 1.ConclusionsIt was found that these compounds have higher selectivities for sigma-1 receptors compared to 1. Quantitatitive structure–activity relationship studies revealed that sigma-1 binding is driven by hydrophobic interactions.Graphical abstractIdentified pharmacophore features for sigma binding.
ACS Omega | 2018
Chia-Ju Hsieh; Kuiying Xu; Iljung Lee; Thomas J. A. Graham; Zhude Tu; Dhruva Dhavale; Paul T. Kotzbauer; Robert H. Mach
A series of chalcone and heterocyclic isosteres, in which the enone moiety was replaced with an isoxazole and pyrazole ring system, was synthesized and their affinities for alpha synuclein (Asyn), amyloid beta (Aβ), and tau fibrils were measured in vitro. The compounds were found to have a modest affinity and selectivity for Asyn versus Aβ fibrils and low affinity for tau fibrils. Insertion of a double bond to increase the extendable surface area resulted in an increase in affinity and improvement in selectivity for Asyn versus Aβ and tau fibrils. The results of this study indicate that compound 11 is a secondary lead compound for structure–activity relationship studies aimed at identifying a suitable compound for positron emission tomography-imaging studies of insoluble Asyn aggregates in Parkinson’s disease.
Nuclear Medicine and Biology | 2005
Zhude Tu; Carmen S. Dence; Datta E. Ponde; Lynne A. Jones; Kenneth T. Wheeler; Michael J. Welch; Robert H. Mach
Current Topics in Medicinal Chemistry | 2010
Zhude Tu; Robert H. Mach
Journal of Medicinal Chemistry | 2001
Simon M. N. Efange; Zhude Tu; Krystyna von Hohenberg; Lynn C. Francesconi; Robertha C. Howell; Marilyn V. Rampersad; Louis J. Todaro; Roger L. Papke; Mei-Ping Kung
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Nabeel Nabulsi; David Weinzimmer; Gabriella Gentile; Marc Laruelle; Zhude Tu; Robert Mach; Yu-Shin Ding; Richard Carson; Yiyun Huang
Society of Nuclear Medicine Annual Meeting Abstracts | 2008
Zhude Tu; Jinbin Xu; Wenhua Chu; Shihong Li; Robert R. Luedtke; Robert H. Mach
Society of Nuclear Medicine Annual Meeting Abstracts | 2014
Xiang Zhang; Hongjun Jin; Junfeng Li; Hao Yang; Hubert Flores; Yi Su; Stanley M. Parsons; Joel S. Perlmutter; Zhude Tu
Society of Nuclear Medicine Annual Meeting Abstracts | 2013
Junfeng Li; Jinda Fan; Hongjun Jin; Prashanth K. Padakanti; Hao Yang; Zhijian Wang; Hubert Flores; Robert H. Mach; Joel S. Perlmutter; Zhude Tu
Society of Nuclear Medicine Annual Meeting Abstracts | 2013
Richard Laforest; Deborah Delano; Carmen S. Dence; Kooresh Shoghi; Sally W. Schwarz; Zhude Tu; Robert H. Mach; Robert J. Gropler